These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32292017)

  • 1. Association between red cell distribution width and response to methotrexate in rheumatoid arthritis.
    Bellan M; Soddu D; Zecca E; Croce A; Bonometti R; Pedrazzoli R; Sola D; Rigamonti C; Castello LM; Avanzi GC; Pirisi M; Sainaghi PP
    Reumatismo; 2020 Apr; 72(1):16-20. PubMed ID: 32292017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis.
    Lange A; Kostadinova L; Damjanovska S; Gad I; Syed S; Siddiqui H; Yousif P; Kowal CM; Shive C; Burant C; Singer N; Bej T; Al-Kindi S; Wilson B; Mattar M; Zidar DA; Anthony DD
    J Rheumatol; 2023 Feb; 50(2):166-174. PubMed ID: 36319020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
    J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis.
    Singh A; Misra R; Aggarwal A
    Rheumatol Int; 2019 Aug; 39(8):1431-1438. PubMed ID: 31203399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.
    Singh A; Patro PS; Aggarwal A
    Clin Rheumatol; 2019 Mar; 38(3):877-884. PubMed ID: 30511295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red cell distribution width and neutrophil-lymphocyte ratio in rheumatoid arthritis.
    Remalante PPM; Salido EO; Penserga EG; Gauiran DTV
    Rheumatol Int; 2020 Oct; 40(10):1631-1637. PubMed ID: 32812079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Plant D; Maciejewski M; Smith S; Nair N; ; Hyrich K; Ziemek D; Barton A; Verstappen S
    Arthritis Rheumatol; 2019 May; 71(5):678-684. PubMed ID: 30615300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis.
    He Y; Liu C; Zeng Z; Ye W; Lin J; Ou Q
    Clin Rheumatol; 2018 Jan; 37(1):161-167. PubMed ID: 29101675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
    Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
    Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis.
    Nair N; Plant D; Verstappen SM; Isaacs JD; Morgan AW; Hyrich KL; Barton A; Wilson AG;
    Rheumatology (Oxford); 2020 Jun; 59(6):1364-1371. PubMed ID: 31598719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating miR-10a as Predictor of Therapy Response in Rheumatoid Arthritis Patients Treated with Methotrexate.
    Hong H; Yang H; Xia Y
    Curr Pharm Biotechnol; 2018; 19(1):79-86. PubMed ID: 29667551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
    Lundström SL; Hensvold AH; Rutishauser D; Klareskog L; Ytterberg AJ; Zubarev RA; Catrina AI
    Arthritis Res Ther; 2017 Aug; 19(1):182. PubMed ID: 28793911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
    Haroon N; Srivastava R; Misra R; Aggarwal A
    J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.